Home › Trials › NCT06453928
Clinical trial Recruiting at 3 sites Interventional Ages 18 and up

Using hybrid closed-loop insulin pumps to improve diabetes management in diverse adults

Official title: Starting Technology in At Risk Type 1 Diabetes (STAR-T1D) Study

Run by University of California, Los Angeles · NCT06453928 · Data updated 2026-11-12

This study is testing if a new type of insulin pump can help adults with poorly controlled Type 1 Diabetes manage their condition better, especially those from different backgrounds who usually have trouble accessing diabetes technology.

Quick facts

Study typeInterventional
Ages18 Years and up
SexAll
Enrollment40 (estimated)
SponsorUniversity of California, Los Angeles
Academic / other
Locations3 sites (Santa Monica, California and 2 other locations)
StatusRecruiting
StartedSeptember 5, 2024
Main results expectedJanuary 31, 2027
Study endsJune 1, 2027
Registry record updatedOctober 29, 2026
Trial IDNCT06453928 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adults with Type 1 Diabetes, an HbA1c greater than 8.5%, who are not currently using an insulin pump and have medical insurance.

Probably not a fit

Patients with significant comorbidities affecting A1c accuracy, cognitive or physical impairments, or those with a limited life expectancy may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This pilot study aims to evaluate the feasibility of using hybrid closed-loop insulin pump therapy in a diverse group of adults with poorly controlled Type 1 Diabetes, specifically those with an HbA1c greater than 8.5%. The study will include 40 participants from various racial and ethnic backgrounds, focusing on those who have historically faced barriers to accessing diabetes technology. By expanding the participant pool beyond typical demographics, the researchers hope to identify facilitators and barriers to effective use of this technology. The study will take place in major health systems in the Los Angeles area, including UCLA and Harbor-UCLA Medical Center.

Why it matters

Potential benefit: If successful, this study could lead to improved diabetes management and health outcomes for underserved populations with Type 1 Diabetes.

How similar studies have gone: While there have been studies on diabetes technology, this approach focusing on diverse and underserved populations is relatively novel.

Who can join: the full rules

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Type 1 Diabetes
* A1c ≥ 8.0%
* Not insulin pump user
* Primary language of English or Spanish
* Have medical insurance coverage

Exclusion Criteria:

* No measured A1c in the past year
* Have comorbidities that can result in inaccurate hemoglobin A1c
* Have cognitive, physical or mental impairment precluding diabetes technology use
* Limited life expectancy (\<1 year)
* Pregnancy

Where it's running

  • UCLA
    Santa Monica, California, United States     Recruiting
  • Olive View-UCLA Medical Center
    Sylmar, California, United States     Recruiting
  • Harbor-UCLA Medical Center
    Torrance, California, United States     Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov ↗ Find more trials like this →
Browse more
Diabetes Mellitus, Type 1 68University of California Los Angeles 1874
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.